Beijing Business Daily (Reporter Ding Ning) On the evening of October 16, Junshi Biosciences (688180) issued an announcement stating that the company's product, a recombinant humanized anti-PD-1 and VEGF bispecific antibody (code: JS207), compared with nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, alterable driver gene (AGA)-negative non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration (FDA) for its clinical trial application.
The announcement shows that JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody independently developed by the company, mainly used for the treatment of advanced malignant tumors. JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively blocking the binding of PD-1 to PD-L1 and PD-L2, and inhibiting the binding of VEGF to its receptors. JS207 has immunotherapy effects.The therapeutic properties of drugs and anti-angiogenic drugs can inhibit the proliferation of vascular endothelial cells by neutralizing VEGF, improve the tumor microenvironment, and increase the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thereby achieving better anti-tumor activity.

https://finance.eastmoney.com/a/202510163536237783.html